Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Patents (Class 514/561)
  • Patent number: 11345654
    Abstract: The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: May 31, 2022
    Assignee: NAVITOR PHARMACEUTICALS, INC.
    Inventor: Silvia Lenzini
  • Patent number: 11278502
    Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 22, 2022
    Assignee: LUPIN LIMITED
    Inventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
  • Patent number: 11273138
    Abstract: The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 15, 2022
    Assignee: BioVentures, LLC
    Inventors: Robert R. Wolfe, Arny Ferrando
  • Patent number: 11224581
    Abstract: An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 18, 2022
    Inventors: Kentaro Nakamura, Kinya Ashida, Akina Sasayama, Yuri Saito
  • Patent number: 11225457
    Abstract: The present invention is related to a process for preparing safinamide and salts thereof, preferably safinamide methanesulfonate, with high yields and high enantiomeric and chemical purity without the need of using highly pure intermediates. The process of the present invention is suitable for the production of safinamide and its salts, preferably safinamide methanesulfonate, at industrial scale.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: January 18, 2022
    Assignee: MEDICHEM, S.A.
    Inventors: Yisong Wen, David Font Gimbernat, Ernesto Durán López
  • Patent number: 11213495
    Abstract: The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 4, 2022
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventor: Hwei-Hsien Chen
  • Patent number: 11203596
    Abstract: Disclosed are compound and methods of using the compounds for modulating ornithine aminotransferase (OAT) activity. The disclosed compound are characterized as analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid which may be formulated as therapeutic agents for treating diseases and disorders associated with ornithine aminotransferase (OAT) activity such as hepatocellular carcinoma and other cancers.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: December 21, 2021
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Matthew J. Moschitto
  • Patent number: 11147780
    Abstract: Disclosed herein is a multidrug pain management package to dispense two or more medicaments to treat pain comprising a primary n-polygon, and one or more concentric m-polygons, wherein each side of the n-polygon and m-polygons have at least n or m-medicament chambers capable of holding the two or more medicaments. Also disclosed herein is a multidrug pain management package comprising a disk, wherein the disk is divided into equally spaced regions, and wherein each region has chambers capable of holding medicaments. Also disclosed herein are single formulations to treat pain.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: October 19, 2021
    Assignee: ALGIA PHARMA, LLC
    Inventors: David L. Steinberg, Joseph Loskove, Hannah Thompson
  • Patent number: 11147926
    Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: October 19, 2021
    Assignee: PIRAMAL CRITICAL CARE, INC.
    Inventors: John J. Foster, Thomas R. Prentice
  • Patent number: 11147785
    Abstract: A composition and methods of administration are provides utilizing Monosodium L-Glutamate Monohydrate in a stabilized form at an alkaline pH.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: October 19, 2021
    Inventors: Jack Mentkow, Lisa Mentkow
  • Patent number: 11135191
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 5, 2021
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, Ephraim Heller, John Spiridigliozzi, Steven Diianni, Evangelos C. Eleftheriou
  • Patent number: 11123320
    Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 21, 2021
    Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
  • Patent number: 11103483
    Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 31, 2021
    Assignee: Eagle Pharmaceuticals, Inc.
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 11078153
    Abstract: Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid-amino transferase (GABA-AT) activity and ornithine aminotransferase (OAT) activity. Some of the enantiomerically pure compounds inhibit OAT activity more potently than the racemic compound. The disclosed compounds may be used to selectively inhibit OAT activity, for example, to treat hepatocellular carcinoma and/or used to selected inhibit GABA-AT activity, for example, to treat neurological diseases and disorders.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 3, 2021
    Assignee: Northwestern University
    Inventor: Richard B. Silverman
  • Patent number: 10973793
    Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: April 13, 2021
    Assignee: AXCELLA HEALTH INC.
    Inventors: William Comb, Michael Hamill, Raffi Afeyan
  • Patent number: 10952973
    Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 23, 2021
    Assignee: NITTO DENKO CORPORATION
    Inventors: Tomohito Takita, Kaiji Fujiwara, Chie Matsumoto, Akinori Sugiyama, Jyun Isayama, Toshinari Honda, Ai Funasaki
  • Patent number: 10934318
    Abstract: The subject invention provides methods and procedures for synthesis and/or semi-synthesis of the novel antibiotic arsinothricin (AST) and derivatives. Arsinothricin (AST), a new broad-spectrum organoarsenical antibiotic, is a non-proteinogenic analog of glutamate that effectively inhibits glutamine synthetase. The subject invention provides chemical synthesis of an intermediate in the pathway of AST synthesis, hydroxyarsinothricin (AST-OH), which can be converted to AST by enzymatic methylation catalyzed by the ArsM As(III) S-adenosylmethionine methyltransferase. The methods provide a source of the novel antibiotic that will be required for future clinical trials. The subject invention also provides AST derivatives as a new class of antibiotics.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: March 2, 2021
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Barry P. Rosen, Stanislaw F. Wnuk, Masafumi Yoshinaga, Md Abu Hasan Howlader, Sk Md Sazzad Hossain Suzol
  • Patent number: 10905670
    Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: February 2, 2021
    Assignee: INTRABIO LTD.
    Inventors: Mallory Factor, Michael Strupp
  • Patent number: 10888571
    Abstract: A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-? and increase mTOR expression in muscle.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: January 12, 2021
    Assignee: Lonza Consumer Health Inc.
    Inventors: Aouatef Bellamine, Ilya Zhivkovich, Ulla Freitas
  • Patent number: 10874626
    Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: December 29, 2020
    Assignee: Nevakar Inc.
    Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
  • Patent number: 10870681
    Abstract: The present invention provides method treating a subject suffering from a clinical condition associated with CXCR4 activity, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein a is 0 or 1; AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine; AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine; Ar1 is an optionally substituted aryl; X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); X2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr), a D-isomer thereof, or absent; X3 is Gly or absent; X4 is Phe, 2Nal, 1Nal, or absent; X5 is Gly or absent; R2 is —OR4 or —NHR5; R4 is H or alkyl; and R5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 22, 2020
    Assignee: MAINLINE BIOSCIENCES LLC
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 10786474
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 29, 2020
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, John Spiridigliozzi
  • Patent number: 10765651
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 8, 2020
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10716855
    Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 21, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Hans Christian Wulf, Gloria Sanclemente
  • Patent number: 10695310
    Abstract: Methods of treatment using D-serine to target brain cells expressing GluN3 subunit-containing triheteromeric NMDARs are disclosed. The methods include inhibiting calcium ion uptake by brain cells, treating epilepsy, and treating seizures by artificially administering D-serine.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 30, 2020
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: Sanjay S. Kumar
  • Patent number: 10660887
    Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
    Type: Grant
    Filed: July 16, 2017
    Date of Patent: May 26, 2020
    Assignee: GLYTECH, LLC
    Inventor: Daniel C. Javitt
  • Patent number: 10654794
    Abstract: Disclosed are a fused tricyclic ?-amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic ?-amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: May 19, 2020
    Assignee: SICHUAN HAISO PHARMACEUTICAL CO., LTD.
    Inventors: Yao Li, Zongjun Shi, Bo Xu
  • Patent number: 10646435
    Abstract: The present invention provides pasty or liquid compositions for applications on mucous membranes of cavities easily reached by hand, having a bio-adhesive prolonged effect or release. The composition includes a polysaccharide matrix agent selected from the group constituting of lambda carrageenan and iota carrageenan. The matrix allows the in situ formation of a matrix film with a reinforced bio-adhesive capacity due to complexation reactions between the polysaccharide matrix agent and the components of the local secretions of the mucous membranes. The compositions can also include a lecithin compound as a reinforcing agent of the intrinsic bio-adhesive properties of the polysaccharide matrix agent. The composition can further include at least one of (a) a hydration medium for the polysaccharide matrix agent, (b) a lecithin co-solvent allowing the dispersion of the micellar lecithin solution in the hydration medium, (c) an additive or additives, and (d) at least one active ingredient.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 12, 2020
    Assignee: CARE & PHARMA PERSPECTIVES SA
    Inventor: Laurence Paris
  • Patent number: 10596136
    Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: March 24, 2020
    Assignee: AXCELLA HEALTH INC.
    Inventors: Manu Chakravarthy, William Comb, Michael Hamill, Tony Tramontin
  • Patent number: 10588882
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 17, 2020
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, John Spiridigliozzi
  • Patent number: 10583138
    Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 10, 2020
    Assignee: GLYTECH, LLC
    Inventor: Daniel C. Javitt
  • Patent number: 10485776
    Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: November 26, 2019
    Assignee: KEMPHYS LTD.
    Inventors: Koichi Shudo, Kiyoshi Sugiyama
  • Patent number: 10426792
    Abstract: Compositions and supplement formulations comprise at least one of Carnitine, Taurine, or derivative forms thereof. In one aspect, the composition or a supplement formulation comprises at least one Amino Acid constituent selected from the group consisting of Carnitine, Taurine, and derivative forms thereof; and at least one Nitrate constituent. In another aspect, the composition or a supplement formulation comprises a Nitrate of a compound selected from the group consisting of Carnitine, Taurine, and derivative forms thereof, wherein the Nitrate is a salt of Nitrate or a mixed salt of Nitrate. The compositions and supplement formulations may be formulated for improving athletic performance, increasing the bioabsorption of Carnitine, Taurine, or derivative forms thereof, or for increasing the vasodilative characteristics.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 1, 2019
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10420783
    Abstract: The present invention relates to a foodstuff comprising feather hydrolysate for use in improving performance during exercise and/or improving recovery after exercise in a dog. It also relates to a method of improving the performance in a dog during exercise and/or improving recovery after exercise, the method comprising administering to a dog a foodstuff which comprises feather hydrolysate.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 24, 2019
    Assignee: Mars, Incorporated
    Inventors: Alexandre Feugier, Delphine Clero
  • Patent number: 10363246
    Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 30, 2019
    Assignee: Ovid Therapeutics Inc.
    Inventor: Matthew During
  • Patent number: 10351608
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 16, 2019
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10328041
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 25, 2019
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10328044
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 25, 2019
    Assignee: SynAgile Corporation
    Inventor: Adam Heller
  • Patent number: 10328042
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 25, 2019
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10307387
    Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: June 4, 2019
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: Sanjay Kumar
  • Patent number: 10306909
    Abstract: The present invention is based on the finding that free amino acids can both negatively or positively influence overall taste of free amino acid-based enteral nutritional compositions, and the amino acids can thus be categorized. A striking balance of both categories of amino acids to arrive at amino acid-based nutritional composition with improved taste, yet not compromising the (regulatory) dietary restrictions on essential amino acids and conditionally essential amino acids.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 4, 2019
    Assignee: N.V. NUTRICIA
    Inventors: Jonathan Rason, Carole Springett
  • Patent number: 10300033
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: May 28, 2019
    Assignee: SynAgile Corporation
    Inventor: Adam Heller
  • Patent number: 10265278
    Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Inventor: Daniel Javitt
  • Patent number: 10255497
    Abstract: The invention relates to a method and to a device for authenticating and/or identifying persons, objects, or service systems. In said method, a material, a construction, a substance, or a composition, or an image thereof, either changes itself or is actively changed, by means of a physical, chemical, or mechanical influence or feature, such that the resulting structure or feature is unforeseeable. If an image of said material, of the construction, of the substance, or the composition recorded at a later time is compared with the image stored in a storage means, the person and/or the object and/or the medium and/or service system is positively authenticated if the material, the construction, the substance, or the composition has at least partially changed between the two times in comparison with the image stored in the storage means.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Inventor: Friedrich Kisters
  • Patent number: 10241093
    Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 26, 2019
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
  • Patent number: 10188635
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of tinnitus.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 29, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10137288
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 27, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10136669
    Abstract: A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 27, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tomoyuki Mine, Naoki Hayashi, Itaru Kon, Kazunori Saima
  • Patent number: 10098856
    Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 16, 2018
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
  • Patent number: 10076573
    Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 18, 2018
    Assignee: Innovo Biopolymers, LLC
    Inventors: Alexander Andrianov, Alexander Marin